Advertisement
GERN vs UTHR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Hold and UTHR is a Hold.
GERN's RSI Oscillator stays in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +3.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in 165 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
GERN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GERN as a result. In 84 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for GERN turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 43 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for GERN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. GERN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.733) is normal, around the industry mean (3.051). P/E Ratio (-8.455) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (16.670) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (4.250) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
UTHR in upward trend: price rose above 50-day moving average on September 30, 2026
UTHR moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on UTHR as a result. In 63 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for UTHR just turned positive on September 30, 2026. Looking at past instances where UTHR's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.
The 10-day moving average for UTHR crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTHR advanced for three days, in 220 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 186 of 266 cases where UTHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
UTHR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. UTHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.030) is normal, around the industry mean (8.179). P/E Ratio (19.891) is within average values for comparable stocks, (-0.806). Projected Growth (PEG Ratio) (2.205) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (7.418) is also within normal values, averaging (181.047).
GERN | UTHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 8 | |
SMR RATING 1..100 | 97 | 48 | |
PRICE GROWTH RATING 1..100 | 81 | 41 | |
P/E GROWTH RATING 1..100 | 14 | 23 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
UTHR's Valuation (71) in the Pharmaceuticals Other industry is in the same range as GERN (92) in the Biotechnology industry. This means that UTHR’s stock grew similarly to GERN’s over the last 12 months.
UTHR's Profit vs Risk Rating (8) in the Pharmaceuticals Other industry is significantly better than the same rating for GERN (100) in the Biotechnology industry. This means that UTHR’s stock grew significantly faster than GERN’s over the last 12 months.
UTHR's SMR Rating (48) in the Pharmaceuticals Other industry is somewhat better than the same rating for GERN (97) in the Biotechnology industry. This means that UTHR’s stock grew somewhat faster than GERN’s over the last 12 months.
UTHR's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for GERN (81) in the Biotechnology industry. This means that UTHR’s stock grew somewhat faster than GERN’s over the last 12 months.
GERN's P/E Growth Rating (14) in the Biotechnology industry is in the same range as UTHR (23) in the Pharmaceuticals Other industry. This means that GERN’s stock grew similarly to UTHR’s over the last 12 months.
| GERN | UTHR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 62% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 66% |
| MACD ODDS (%) | 1 day ago 77% | 5 days ago 71% |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 67% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 69% |
| Advances ODDS (%) | 1 day ago 77% | 5 days ago 70% |
| Declines ODDS (%) | 5 days ago 80% | 7 days ago 60% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 60% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GERN’s FA Score shows that 1 FA rating(s) are green while UTHR’s FA Score has 2 green FA rating(s).
- GERN’s FA Score: 1 green, 4 red.
- UTHR’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GERN’s TA Score shows that 4 TA indicator(s) are bullish while UTHR’s TA Score has 6 bullish TA indicator(s).
- GERN’s TA Score: 4 bullish, 4 bearish.
- UTHR’s TA Score: 6 bullish, 4 bearish.
Price Growth
GERN (@Biotechnology) experienced а -19.13% price change this week, while UTHR (@Pharmaceuticals: Generic) price change was +1.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -12.05%, and the average quarterly price growth was -17.02%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.23%. For the same industry, the average monthly price growth was -7.21%, and the average quarterly price growth was +2.47%.
Reported Earning Dates
GERN is expected to report earnings on Nov 04, 2026.
UTHR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-2.09% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-1.23% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
GERN and
Correlation & Price change
A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.
| Ticker / NAME | Correlation To GERN | 1D Price Change % | ||
|---|---|---|---|---|
| GERN | 100% | +0.10% | ||
| SER - GERN | 66% Loosely correlated | -1.08% | ||
| VCYT - GERN | 44% Loosely correlated | +2.63% | ||
| TVTX - GERN | 40% Loosely correlated | +0.30% | ||
| RYTM - GERN | 39% Loosely correlated | -7.49% | ||
| EDIT - GERN | 39% Loosely correlated | +1.17% | ||
More | ||||
UTHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, UTHR has been loosely correlated with MNKD. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if UTHR jumps, then MNKD could also see price increases.
| Ticker / NAME | Correlation To UTHR | 1D Price Change % | ||
|---|---|---|---|---|
| UTHR | 100% | +0.87% | ||
| MNKD - UTHR | 38% Loosely correlated | +2.19% | ||
| GERN - UTHR | 37% Loosely correlated | +0.10% | ||
| ALNY - UTHR | 36% Loosely correlated | +1.20% | ||
| CBIO - UTHR | 36% Loosely correlated | +1.16% | ||
| INSM - UTHR | 35% Loosely correlated | -4.46% | ||
More | ||||